The historical rank and industry rank for Clarus Therapeutics Holdings's Price-to-Tangible-Book or its related term are showing as below:
CRXTQ's Price-to-Tangible-Book is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.42 * Ranked among companies with meaningful Price-to-Tangible-Book only.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Clarus Therapeutics Holdings Price-to-Tangible-Book Chart
Competitive Comparison of Clarus Therapeutics Holdings's Price-to-Tangible-Book
For the Drug Manufacturers - Specialty & Generic subindustry, Clarus Therapeutics Holdings's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clarus Therapeutics Holdings's Price-to-Tangible-Book Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Clarus Therapeutics Holdings's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Clarus Therapeutics Holdings's Price-to-Tangible-Book falls into.
Clarus Therapeutics Holdings Price-to-Tangible-Book Calculation
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Clarus Therapeutics Holdings Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Clarus Therapeutics Holdings's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Business Description
Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is focused on focused on the commercialization of JATENZO (testosterone undecanoate), the first and only oral testosterone replacement, or testosterone replacement therapy, and JATENZO is the sole source of company's revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRXTQ has been successfully added to your